Arzerra (ofatumumab) / Novartis, Genmab - LARVOL DELTA

Real-World Overall Survival, Richter's Transformation, and Secondary Primary Malignancy Rates in CLL Treated With Fixed-Duration Venetoclax-Based Therapy Versus Indefinite BTK Inhibitor Monotherapy: A TriNetX Propensity-Matched Analysis (SOHO 2026) - "Background: The chronic lymphocytic leukemia (CLL) treatment landscape is defined by two dominant targeted therapy paradigms: fixed-duration venetoclax-based combinations (venetoclax and obinutuzumab or venetoclax and ofatumumab [Ven-O/Ofa]) and indefinite Bruton tyrosine kinase inhibitor (BTKi) monotherapy (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib). In this propensity-matched real-world analysis of 2546 patients with CLL, fixedduration venetoclax-based therapy was associated with improved 5-year OS and lower RT rates compared with indefinite BTKi monotherapy. SPM rates were largely comparable, although higher skin cancer incidence with Ven-O/Ofa warrants further investigation and highlights the importance of dermatologic surveillance in this population."

Clinical • Monotherapy • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Basal Cell Carcinoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Richter's Syndrome • Skin Cancer • Squamous Cell Carcinoma

Ofatumumab Therapy and Long-Term Seizure Outcomes of Patients With Relapsing Anti-NMDA Receptor Encephalitis. (PubMed, Ann Clin Transl Neurol) - "Ofatumumab showed substantial improvement in long-term seizure outcomes in patients with relapsing anti-NMDA receptor encephalitis, particularly those presenting with seizures as a predominant clinical feature."

Journal • CNS Disorders • Epilepsy • Immunology • Psychiatry

Multimodal Single-Cell Profiling Reveals Distinct Systemic Immune Remodeling Following Ocrelizumab vs Ofatumumab Therapy (ACR Convergence 2026) - No abstract available

Immunology • Inflammation

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study (ASH 2022) - "Pts with CD20+ disease (≥1% cells) received 8 doses of ofatumumab (2000 mg) or rituximab (375 mg/m2)...Beginning with pt #39, INO at a dose of 0.3 mg/m2 on day 1 and 8 was added to the 2 cycles of MTX/Ara-C and to 2 cycles of blinatumomab consolidation (4 total cycles with INO)... The addition of INO to hyper-CVAD with sequential blinatumomab is safe and highly effective as frontline treatment of Ph-negative B-cell ALL. This study shows the feasibility of incorporating both INO and blinatumomab into the frontline treatment of pts with B-cell ALL. Outcomes of the pts treated in the INO cohort are particularly promising."

Clinical • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • CNS Disorders • Hematological Malignancies • Hepatology • Leukemia • Oncology • Transplantation • ABL1 • CD20 • CRLF2 • KMT2A • NUP214 • POMP • TP53

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) "Miro" Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy (ASH 2023) - "Pts who were MRD+ by both NEST and RQ in the BM a/o PB after IFRT or who became MRD+ during the follow-up were treated with 8 weekly doses of the anti-CD20 monoclonal antibody ofatumumab (OFA)...A consolidation strategy with more effective agent should be advisable. With these limits, a clinical advantage of the MRD-driven treatment strategy is suggested, although not largely applicable."

Clinical • IO biomarker • P2 data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • BCL2

Eculizumab treatment in the salvage therapy of MOGAD: a case report. (PubMed, Front Immunol) - "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare inflammatory demyelinating disorder of the central nervous system. Ofatumumab may be a viable option for maintenance therapy during remission. These findings may provide valuable insights for future clinical research."

Journal • CNS Disorders • Epstein-Barr Virus Infections • Infectious Disease • Solid Tumor

Lymphoplasmapheresis for Refractory Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report. (PubMed, J Clin Apher) - "We report a 61-year-old woman with refractory anti-NMDAR encephalitis who showed limited improvement after corticosteroids, intravenous immunoglobulin, and ofatumumab...At 5-month follow-up after LPE, she maintained sustained recovery, with a Clinical Assessment Scale in Autoimmune Encephalitis score of 6 and a modified Rankin Scale score of 2. This case supports a close temporal association between LPE and clinical and immunological improvement, although causality cannot be definitively established from a single case."

Journal • CNS Disorders • Immunology

Sequential efgartigimod and ofatumumab for stiff-person syndrome: a case report illustrating a pathophysiology-informed strategy and literature review. (PubMed, Front Immunol) - "This sequential strategy resulted in substantial and sustained clinical improvement (mRS score 4 to 1, Barthel Index 75 to 100) and a reduced clonazepam requirement despite persistently high anti-GAD65 antibody titers, demonstrating efficacy beyond mere antibody reduction. This case provides preliminary clinical experience with a sequential efgartigimod-ofatumumab strategy in treatment-resistant SPS. This approach, which combines rapid antibody clearance with sustained B-cell suppression, not only affirms the role of ofatumumab in long-term immunomodulation but also highlights the potential synergy of sequential administration, warranting further investigation."

Journal • Review • CNS Disorders • Immunology

Contemporary review of primary membranous nephropathy. (PubMed, Front Immunol) - "Very high-risk cases (declining eGFR, complications of nephrosis) should receive alternating steroids/cyclophosphamide...Reduced bioavailability may respond to redosing or use of the more potent B-cell depleters, obinutuzumab or ofatumumab, neither of which cross react with anti-rituximab antibodies...In PLA2R-positive cases, antibody reemergence or titers failing to decrease post-transplantation indicates protocol biopsy. Recurrence is not likely to remit and should prompt consideration of rituximab."

Journal • Review • Glomerulonephritis • Immunology • Nephrology • Renal Disease • Transplantation

Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China. (PubMed, Ther Adv Neurol Disord) - "This study delineates a distinct clinical-radiological profile of MOGAD in Northern China, characterized by a high frequency of cortical encephalitis. Furthermore, it provides preliminary evidence that ofatumumab may be a potential steroid-sparing therapeutic option for MOGAD."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Pediatrics • Solid Tumor

Baseline Data of Austrian RMS Patients Treated Earlier vs. Later with Ofatumumab: The KRONOS Study Population (EAN 2026) - P | "KRONOS patients were predominantely female with low baseline disability. Most remained relapse-free after starting Ofatumumab, and a minority showed improved EDSS. Longitudinal data will clarify longer-term outcomes and effects of early versus late Ofatumumab use."

Clinical

Ofatumumab in Refractory Anti-GABABR Encephalitis with Active Infection (EAN 2026) - No abstract available

CNS Disorders • Infectious Disease

Effectiveness and safety of ofatumumab treatment in RRMS patients – one site RWE experience study (EAN 2026) - No abstract available

Clinical • Multiple Sclerosis

Clinical heterogeneity and immunotherapy outcomes in anti-GAD65 antibody-associated autoimmune encephalitis: a retrospective study. (PubMed, Ther Adv Neurol Disord) - "Maintenance therapy with mycophenolate mofetil or biologics (e.g., ofatumumab, telitacicept) elicited heterogeneous serological responses, including antibody titer rebound despite clinical stability. Coexisting antibodies may exacerbate neuronal injury through mechanisms such as antigen unmasking and antibody-dependent cellular cytotoxicity. Persistent antibody elevation and subclinical immune activity underscore the necessity of integrating multimodal biomarkers and developing personalized treatment strategies."

Heterogeneity • IO biomarker • Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Diabetes • Endocrine Disorders • Epilepsy • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus • CD20 • CD68 • CD8

PATIENT-REPORTED OUTCOMES AND DISEASE PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND GAP ANALYSIS (EHA 2026) - "The first publication reported global health status and fatigue before and after disease progression among 428 patients randomized to chlorambucil or chlorambucil with ofatumumab who had at least one PRO measurement...The second publication reported a post-hoc analysis among the 560 patients with relapsed/refractory CLL/SLL with at least one evaluable PRO who were randomized to zanubrutinib or ibrutinib...Summary/Conclusion This study highlights a gap in evidence regarding patient-reported symptoms and disease progression in CLL/SLL. Further work is needed to develop a consensus-driven symptomatic progression composite endpoint in CLL/SLL to support future clinical and HTA decision-making."

Clinical • Patient reported outcomes • Review • Chronic Lymphocytic Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Insomnia • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Sleep Disorder • Small Lymphocytic Lymphoma

Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial. (PubMed, Front Neurol) - P3 | "80 patients will receive B-cell depleting agent (anti-CD20 mAb ofatumumab) followed by anti-CD38 mAb daratumumab, 80 patients will receive B-cell depleting agent ofatumumab alone, and 40 receive repeated IVIG or plasmapheresis. This combined regimen may provide a new treatment option for NMDARE. https://clinicaltrials.gov/study/NCT06867991, identifier (NCT06867991)."

Journal • CNS Disorders • Critical care • Immunology • Psychiatry

Rituximab-induced serum sickness: new insights on a rare side effect based on a multicenter study of 94 patients (EULAR 2026) - "However, no similar reactions were observed following changes in anti-CD20 therapy with obinutuzumab (n=39), ocrelizumab (n=2) or ofatumumab (n=1). Re-challenge with rituximab consistently induced relapse, underscoring the need for rituximab contraindication, especially since a rechallenge is associated with a loss of efficacy in case of immunization (3). Other anti-CD20 antibodies could be considered, without evidence of cross-reaction regarding serum sickness."

Adverse events • Clinical • ANCA Vasculitis • Hematological Malignancies • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Sjogren's Syndrome • Thrombocytopenia • Thrombocytopenic Purpura • Urticaria • Vasculitis • CRP

Assessing the Risk of Drug-Induced Influenza-Like Illness: A Disproportionality Analysis of Two Decades of FAERS Data (2004-2025). (PubMed, Curr Drug Saf) - "This first comprehensive FAERS study identifies key drugs associated with ILI, including interferon β-1a, evolocumab, ofatumumab, interferon β-1b, and zoledronic acid. Clinical monitoring for drug-induced ILI is essential to enhance medication safety."

Journal • Cardiovascular • Infectious Disease • Influenza • Musculoskeletal Diseases • Oncology • Respiratory Diseases • IFNB1

Revisiting the Ofatumumab Epitope on CD20 through Integrative Molecular Dynamics and Flow Cytometry Analyses. (PubMed, Comput Struct Biotechnol J) - "The single-chain variable fragment recognizes a membrane-proximal epitope primarily centered on extracellular loop 2b/extracellular helix 2, stabilized by hydrophobic and electrostatic interactions involving the Y105-Y107-Y169 cluster and Arg228, while mutations at Asp99 and Tyr107 disrupted paratope stability and markedly reduced cellular binding. These results refine the molecular model of ofatumumab single-chain variable fragment-CD20 recognition and provide atomic-level insights that may assist the design of next-generation anti-CD20 and chimeric antigen receptor T-cell therapeutics."

Journal • Hematological Malignancies • Immunology • Oncology • CD20

Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neuromyelitis optica spectrum disorder: a case series. (PubMed, Front Immunol) - "Among the 10 patients, one was switched to the anti-CD20 monoclonal antibody ofatumumab, two to the anti-CD19 monoclonal antibody inebilizumab, two to the IL-6 receptor antagonist satralizumab, and one to the C5 complement inhibitor eculizumab, while 4 transitioned to de-escalations (mycophenolate mofetil, intravenous immunoglobulin, or steroids). In this descriptive case series of 10 patients with RTX-resistant NMOSD, those who switched to inebilizumab, satralizumab, or eculizumab appeared to have fewer relapses and a favorable safety profile compared to those receiving de-escalation strategies or ofatumumab. These real-world observations provide hypothesis-generating data that may inform clinical decision-making and warrant validation in larger, prospective cohorts."

Journal • Retrospective data • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases • IL6

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab. (PubMed, Ann Clin Transl Neurol) - "Ofatumumab was associated with a lower relapse risk compared with rituximab in patients with MOGAD."

Journal • CNS Disorders • Solid Tumor

Ofatumumab in chronic inflammatory demyelinating polyradiculoneuropathy associated with monoclonal gammopathy of undetermined significance: a case report. (PubMed, Front Immunol) - "Despite initial therapies including intravenous immunoglobulin, efgartigimod, and immunosuppressants, he experienced recurrent relapses. This case underscores the potential of B cell directed therapy for refractory MGUS associated neuropathies, offering a novel approach when conventional immunotherapies fail. Further multicenter studies are warranted to establish standardized protocols and optimize long term outcomes through combination regimens targeting both B cell and plasma cell compartments."

Journal • Hematological Malignancies • Monoclonal Gammopathy • Pain

Characterization of Immune Reconstitution Patterns in B-cell Subsets Mediated by B-cell Targeted Therapies (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban) - "To analyze the reconstitution patterns of fine B-cell subsets in patients following treatment with the CD20 monoclonal antibody ofatumumab and the CD19 monoclonal antibody inebilizumab, and to evaluate the clinical application value of individualized fine B-cell subset dynamic profiling in guiding targeted therapy strategies...Increased plasmablasts, aberrant memory B-cell proliferation, and rebounding Dsg antibodies may signal potential adverse events. These findings support monitoring fine B-cell subsets for precise immunological assessment to guide personalized treatment."

Journal • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Comparison With Rituximab (AAN 2026) - "Adverse events were reported in 12 patients (54.55%) treated with ofatumumab, most of which were mild and occurred after the initial dose. Conclusions Ofatumumab showed favorable efficacy in reducing relapses in patients with MOGAD compared to rituximab."

CNS Disorders • Solid Tumor

Considerations for infection risks identified in target safety review. (PubMed, J Toxicol Sci) - "Our survey shows clear immune-related toxicity in nonclinical studies of CD20 inhibitors (obinutuzumab, ofatumumab, rituximab), TNF-alpha inhibitors (adalimumab, golimumab), and IL-6R antagonists (sarilumab, tocilizumab). Although nonclinical toxicity studies sometimes provided insights into potential infection risks which can be anticipated by its target, their predictive power for specific mechanism of actions and infections appeared limited. Understanding the MOAs and biological background of the drug through the TSR and identifying and mitigating risks early in the project are essential for the safe development of new therapeutic agents."

Adverse events • Journal • Infectious Disease • CD20 • IL17A • IL1B • IL23A • IL6R